Dr. Sascha Tuchman, MD
Claim this profileUNC Lineberger Comprehensive Cancer Center
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
9 reported clinical trials
12 drugs studied
Area of expertise
1Multiple Myeloma
Stage III
Stage IV
2Plasma Cell Neoplasm
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Sascha Tuchman, MD is currently running
Iberdomide
for Multiple Myeloma
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
Recruiting1 award Phase 210 criteria
Isa-Rd Combo Therapy
for Multiple Myeloma
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.
Recruiting1 award Phase 210 criteria
More about Sascha Tuchman, MD
Clinical Trial Related4 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Sascha Tuchman, MD has experience with
- Lenalidomide
- Dexamethasone
- Iberdomide
- Idecabtagene Vicleucel
- Isatuximab
- Ixazomib
Breakdown of trials Sascha Tuchman, MD has run
Multiple Myeloma
Plasma Cell Neoplasm
Amyloidosis
Monoclonal Gammopathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sascha Tuchman, MD specialize in?
Sascha Tuchman, MD focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved Stage III patients, or patients who are Stage IV.
Is Sascha Tuchman, MD currently recruiting for clinical trials?
Yes, Sascha Tuchman, MD is currently recruiting for 4 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Sascha Tuchman, MD has studied deeply?
Yes, Sascha Tuchman, MD has studied treatments such as Lenalidomide, Dexamethasone, Iberdomide.
What is the best way to schedule an appointment with Sascha Tuchman, MD?
Apply for one of the trials that Sascha Tuchman, MD is conducting.
What is the office address of Sascha Tuchman, MD?
The office of Sascha Tuchman, MD is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.